BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 15, 2024
See today's BioWorld
Home
» Failed Fragile X trial holds design lessons
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Failed Fragile X trial holds design lessons
Jan. 15, 2016
By
Anette Breindl
No Comments
Detailed data from two phase IIb trials of the metabotropic glutamate receptor 5 (mGluR5) blocker mavoglurant (AFQ056, Novartis AG) for the treatment of Fragile X syndrome were published in Science Translational Medicine this week.
BioWorld